Welcome to our dedicated page for Sohm news (Ticker: SHMN), a resource for investors and traders seeking the latest updates and insights on Sohm stock.
SOHM Inc. (SHMN) regularly issues news updates that highlight its activities as a pharmaceutical and biotechnology company specializing in generic drugs, gene-editing tools, health and wellness solutions, and biotechnology-driven cosmeceuticals. Many of its announcements focus on progress in gene editing technologies, particularly its proprietary ABBIE genome-engineering platform, as well as corporate developments and strategic initiatives.
Readers of this news feed can expect coverage of gene editing platform milestones, such as technical advances in ABBIE, including Cas9-guided integrase work and later developments using a dCas12a domain to modify cultured human cells. The company has reported the creation of specialized cellular tools, including an ovarian cancer cell line with GYS1 overexpression for drug discovery applications, and it uses news releases to describe the scientific and research implications of these efforts.
SOHM’s news also includes intellectual property and regulatory developments, such as the allowance of a divisional patent in South Korea for Cas9 retroviral integrase and recombinase systems, and commentary on evolving regulatory frameworks for genome-editing technologies. Corporate and strategic updates appear as well, including facility relocation to a commercialization site in Vista, California, leadership and board appointments, and stated goals to enter biotechnology-driven cosmeceuticals.
In addition, the company reports on enhancements to its digital presence, including a redesigned corporate website and plans for an e-commerce platform to support cosmeceuticals, nutraceuticals, and over-the-counter products. For investors, researchers, and industry observers, this news page offers a centralized view of SOHM’s public communications on its gene editing work, broader product directions, governance changes, and operational expansion.
SOHM (OTCID:SHMN) on November 6, 2025 released a technical white paper describing ABBIE, a Cas9-guided integrase platform that enables targeted donor-DNA integration without double-strand breaks or viral vectors. Using ABBIE, the team generated SKOV3-GYS1, an ovarian cancer cell line with stable overexpression of glycogen synthase 1 to support drug-discovery assays.
Key technical findings include non-viral, DSB-free integration, ~3× GYS1 protein levels versus parental SKOV3, >5× GYS1 catalytic activity, and whole-genome sequencing showing a single integration event in an intergenic locus. The company notes target-site variability and ongoing work to refine insertion precision. SOHM invites partnerships to apply ABBIE-engineered models for assay and screening development.
SOHM (OTCID:SHMN) acknowledged recent FDA commentary and industry analyses noting an evolving regulatory framework for genome‑editing technologies on November 4, 2025. The company said regulators are increasingly focused on precision-engineered tools, non-viral delivery methods, and scalable manufacturing.
SOHM is advancing its proprietary ABBIE genome‑engineering platform in preclinical development; ABBIE is described as a programmable enzyme architecture designed to enable DNA‑insertion events without viral vectors. Management emphasized ongoing preclinical work on safety, mechanism, and reproducibility.
SOHM Inc. (OTCID:SHMN) has secured a new patent allowance in South Korea for its innovative gene-editing technology. The patent covers the company's ABBIE gene-editing platform, which combines dCas9 with retroviral integrases for targeted DNA sequence incorporation.
The approved technology, titled "CAS9 Retroviral Integrase and CAS9 Recombinase Systems," strengthens SOHM's global intellectual property portfolio, following previous successes in Europe. This advancement is particularly significant for developing next-generation allogeneic CAR-T therapies and regenerative medicine applications.
SOHM, Inc. (OTCID:SHMN) announced the relocation of its operations to a new 24,000 square-foot commercialization facility in Vista, California. The strategic facility features a 50-50 split between office/lab space and warehouse space, designed to support manufacturing, R&D, and biotech commercialization activities.
Located at 1396 Poinsettia Avenue within the Poinsettia Business Park, this expansion aims to accelerate SOHM's growth strategy, support new product launches, and strengthen its presence in high-growth healthcare markets. The company expects the move to enhance operational efficiency, streamline product development, and facilitate new partnerships within Southern California's life sciences ecosystem.
SOHM (OTC:SHMN) has achieved a significant breakthrough in gene editing technology with its proprietary ABBIE platform version 2. The company successfully demonstrated that its advanced dCas12a domain can effectively modify human cells, enabling multi-target editing capabilities through crRNA arrays.
The company has also successfully cloned an ovarian cancer cell line with confirmed GYS1 enzyme overexpression, demonstrating immediate commercial applications in drug screening, research partnerships, and diagnostic development. This positions SOHM for strategic partnerships and licensing opportunities in the rapidly growing genome editing market, projected to reach $25 billion by 2030 with a CAGR of 16.1%.
SOHM Inc (OTC:SHMN), a pharmaceutical and biotechnology company, has launched its redesigned website at SOHM.com. The new website features improved navigation, enhanced product information, and comprehensive investor resources.
Key improvements include an intuitive user interface, detailed product ordering capabilities, updated information about their ABBIE genome editing platform, and expanded investor relations materials. Additionally, the company announced plans to launch an e-commerce platform at store.sohm.com in the coming days to support their B2C strategy for cosmeceuticals, nutraceuticals, and OTC products.
SOHM Inc. (OTC PINK:SHMN), a pharmaceutical and biotechnology company, has announced the appointment of Ravi Kapoor as an Independent Director to its Board. Mr. Kapoor brings over 30 years of experience in corporate law, mergers and acquisitions (M&A), and financial management.
Mr. Kapoor currently serves as the proprietor of Ravi Kapoor & Associates and is a partner at Yan Advisory Services LLP and Amity Consultants LLP. His extensive qualifications include M.Com, LLB, FCS, CAIIB, AMIMA, and PGDIPR. He has previously served on the boards of notable companies including Concord Biotech Limited and Sanghi Industries Limited (an Adani Group enterprise).
SOHM (OTC PINK:SHMN), a pharmaceutical and biotechnology company, has announced its strategic expansion into biotechnology-based cosmeceuticals. The company plans to leverage its biotech division to develop advanced skincare solutions incorporating biologically sourced actives such as exosomes, peptides, and regenerative proteins.
Under the guidance of Dr. Lucia Piccotti, SOHM's Cosmeceuticals expert and Health Advisory board member, the company will focus on cell culture and fermentation methods for producing high-purity cosmetic ingredients, along with advanced formulation strategies to enhance absorption, stability, and skin bioactivity. This initiative aligns with SOHM's strategic vision of expanding into high-value, innovation-focused product categories.
FAQ
What is the current stock price of Sohm (SHMN)?
What is the market cap of Sohm (SHMN)?
